The Food and Drug Administration has approved capivasertib, marketed as Truqap, with fulvestrant for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors carry qualifying alterations in PIK3CA, AKT1 or PTEN. The November 16 approval introduces the first AKT inhibitor into routine U.S. breast-cancer treatment and pairs the drug with biomarker testing to identify the patients most likely to benefit.

In the biomarker-altered population of the pivotal CAPItello-291 trial, the combination cut the risk of disease progression or death by 50% compared with fulvestrant alone. Median progression-free survival was 7.3 months with capivasertib plus fulvestrant versus 3.1 months with placebo plus fulvestrant, establishing a new targeted option for a group whose cancers have often progressed despite endocrine therapy and, in many cases, CDK4/6 inhibition.

CAPItello-291 tested a pathway central to endocrine resistance

The randomized, double-blind phase 3 trial enrolled 708 patients with HR-positive, HER2-negative advanced breast cancer. According to the New England Journal of Medicine report, 289 participants, or 40.8%, had tumors with alterations in the AKT pathway. Nearly seven in ten participants had previously received a CDK4/6 inhibitor for advanced disease, making the study closely relevant to current treatment patterns.

In the overall trial population, median progression-free survival was 7.2 months with capivasertib plus fulvestrant and 3.6 months with placebo plus fulvestrant, a 40% relative reduction in the risk of progression or death. In the biomarker-altered group on which the FDA indication is focused, the hazard ratio improved to 0.50. The study's ClinicalTrials.gov record documents the randomized design, eligibility requirements and dual primary progression-free-survival endpoints.

The biology behind the result is important. PIK3CA, AKT1 and PTEN are components of the PI3K-AKT signaling pathway, which can promote tumor growth and contribute to resistance to endocrine treatment. Capivasertib inhibits all three AKT isoforms. By pairing pathway inhibition with fulvestrant, which degrades the estrogen receptor, the regimen attacks both estrogen signaling and a major escape pathway used by resistant tumors.

The FDA ties treatment to genomic selection

The approval applies specifically to patients whose cancers contain one or more qualifying PIK3CA, AKT1 or PTEN alterations detected by an FDA-approved test. At the same time, the agency approved FoundationOne CDx as a companion diagnostic for selecting patients. The FDA's companion-diagnostic listing records the November 16 authorization for the assay in connection with Truqap and fulvestrant.

That requirement makes genomic testing part of the treatment pathway rather than an optional research exercise. For patients whose disease has progressed after endocrine-based therapy, the result of tumor testing can now determine eligibility for a newly approved drug. This is a familiar model in HER2-positive and other molecularly defined cancers, but the capivasertib approval broadens the number of actionable genomic pathways in the much larger HR-positive population.

AstraZeneca's approval announcement estimates that alterations in PIK3CA, AKT1 and PTEN collectively occur in as many as half of patients with advanced HR-positive breast cancer. The company also notes that the FDA reviewed the application under Project Orbis, which permits coordinated review with international regulatory authorities.

An intermittent dosing schedule balances pathway inhibition and toxicity

Truqap is given as 400 mg orally twice daily for four consecutive days followed by three days off each week, in combination with fulvestrant. The FDA's Drug Trials Snapshot describes the regimen and the 708-patient evidence base supporting approval. The intermittent schedule is designed to provide sustained pathway inhibition while allowing recovery from toxicities that can accompany AKT blockade.

Adverse events require active management. In the trial, diarrhea and rash were among the most prominent toxicities. AstraZeneca reported diarrhea in 72% and cutaneous adverse reactions in 58% of patients receiving capivasertib, with grade 3 or 4 skin reactions in a smaller subset. Hyperglycemia is also a recognized risk because the PI3K-AKT pathway is involved in metabolic regulation.

These risks mean the new therapy is not simply another endocrine pill. Clinicians will need to monitor glucose, skin reactions, gastrointestinal symptoms and drug interactions, and may need to interrupt, reduce or discontinue treatment. The FDA's indication also excludes patients whose tumors lack the specified genomic alterations, keeping the benefit-risk calculation anchored to the subgroup in which the strongest evidence was demonstrated.

A new option after endocrine therapy resistance

The clinical need is substantial. Hormone receptor-positive disease accounts for the majority of breast cancers, and endocrine therapy is highly effective for many patients. But advanced tumors often develop resistance, including after combinations of endocrine therapy with CDK4/6 inhibitors. Once resistance develops, treatment decisions become increasingly dependent on molecular features and prior therapy.

Earlier CAPItello-291 results presented in 2022 had already shown the 40% risk reduction in the full population and 50% reduction in the altered subgroup. This week's regulatory decision converts those findings into an available, biomarker-defined treatment pathway.

The approval does not establish that every patient with advanced HR-positive disease should receive capivasertib, nor does progression-free survival alone answer the still-maturing question of overall survival. It does, however, add a first-in-class mechanism precisely where many patients need another endocrine-based option before or instead of moving to conventional chemotherapy.

For oncology practice, the immediate implication is clear: testing for PIK3CA, AKT1 and PTEN alterations now carries a new therapeutic consequence. In a treatment landscape increasingly organized around molecular resistance mechanisms, the Truqap approval makes the AKT pathway a directly actionable target in advanced HR-positive, HER2-negative breast cancer.